A phase II trial of high dose cytarabine and fludarabine without anthracycline for patients with core binding factor acute myeloid leukaemia, measuring efficacy, safety and monitoring minimal residual disease (AMLM13)

Dataset includes data for 53 patients in a rare and targeted patient population Dataset includes demographic data, diagnostic, treatment data, outcome data Unpublished data regarding safety and efficacy of medication used in AML patients who underwent bone marrow transplant are censored from this study

本数据集包含53例来自罕见且特定患者群体的患者数据，涵盖人口统计学数据、诊断数据、治疗数据及结局数据。针对接受骨髓移植的急性髓系白血病（AML）患者所用药物的安全性与有效性相关未发表数据，未纳入本研究。